Method of eliciting an immune response against respiratory syncytial virus
AssigneeCodagenix Inc.
InventorsSteffen Mueller, John Robert Coleman, Sybil Tasker, Anna Kushnir
Life of this patent
Estimating the term…
Abstract
The present invention provides for methods of vaccination and eliciting a IgA immune response and cellular immune response, including T-cell immune response by administering a deoptimized respiratory syncytial virus (RSV).
Claims42
A method of eliciting an immune response in a subject, comprising
- intranasally administering one or more doses of an effective amount of a composition comprising a deoptimized respiratory syncytial virus (RSV) to the subject to elicit the immune response,
- wherein the effective amount is about 103-109 focus forming units (FFU) of the deoptimized RSV,
- wherein the immune response comprises IgA immune response, cellular immune response or both.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of eliciting an T-cell immune response in a subject, comprising:
- intranasally administering a first dose of an effective amount of a composition comprising a deoptimized respiratory syncytial virus (RSV) to the subject to elicit the T-cell immune response;
- and
- intranasally administering a second dose of the effective amount of the composition comprising the deoptimized RSV about 28-35 days after the first dose,
- wherein the effective amount is about 106 or about 2×106 focus forming units (FFU) of the deoptimized RSV, wherein the deoptimized RSV comprises the genome or anti-genome having the sequence of SEQ ID NO:1, and wherein eliciting the T-cell immune response comprises an increase in T-cell response as compared to a prevaccination timepoint.
A method of eliciting an T-cell immune response in a subject, comprising:
- intranasally administering a first dose of an effective amount of a composition comprising a deoptimized respiratory syncytial virus (RSV) to the subject to elicit the immune response;
- intranasally administering a second dose of the effective amount of the composition comprising the deoptimized RSV about 28-35 days after the first dose,
- wherein the effective amount is about 105 or about 2×105 focus forming units (FFU) of the deoptimized RSV, wherein the deoptimized RSV comprises the genome or anti-genome having the sequence of SEQ ID NO:1, and wherein eliciting the T-cell immune response comprises an increase in T-cell response as compared to a prevaccination timepoint.
A method of eliciting an IgA immune response, cellular immune response or both in a subject, comprising:
- intranasally administering a first dose of an effective amount of a composition comprising a deoptimized respiratory syncytial virus (RSV) to the subject to elicit the immune response;
- and
- intranasally administering a second dose of the effective amount of the composition comprising the deoptimized RSV about 28-35 days after the first dose;
- wherein the effective amount is about 2×105 focus forming units (FFU) of the deoptimized RSV, wherein the deoptimized RSV comprises the genome or anti-genome having the sequence of SEQ ID NO:1, and wherein an enzyme-linked immune absorbent spot (ELISpot) analysis of peripheral blood mononuclear cells (PBMCs) from the subject shows at least a 1.3 fold increase of spot forming units (SFU) between a baseline value and a highest value during a post vaccination timepoint,
- OR
- wherein the effective amount is about 2×106 focus forming units (FFU) of the deoptimized RSV, wherein the deoptimized RSV comprises the genome or anti-genome having the sequence of SEQ ID NO:1, and wherein eliciting the immune response comprises at least a 2.4 fold rise in IgA levels in the subject.
Dependencies are inferred from the claim text.